Home / Knowledge Centre /

Demystifying Complex Clinical Trial Kit Preparation

Best practices can help ensure supply chain flexibility and viability for biologic drugs in clinical trials.

Developments in biologics and personalized medicines are reshaping the clinical trial landscape. According to Grandview Research, the global biologics market is anticipated to reach $398 billion by 2025, with growth supported by faster drug approval processes (1). Simultaneously, the increasing prevalence of cancer and rare diseases is providing the catalyst for investment in the development of targeted therapies. These precision medicines, which are tailor-made to meet unique patient needs, are expected to reach $85 billion over the next five years, representing a substantial 9.9% compound annual growth rate.

Read more on this article by clicking here.

View Resource

Our Expert

Please complete this form to view the Article

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies